Product Profile - Overview

		ASAQ to treat malaria = Fixed dose combination of Artesunate + Amodiaquine
Launched in 2007 The concrete results of an innovative partnership between DNDi and Sanofi Meets the latest WHO guidelines for malaria treatment in Africa Simple regimen: 1 or 2 tablets once a day for 3 days Available at only 0.5$ for children, 1$ for adults Meets the highest standard of quality Made in the South for use in the South: ASAQ is produced in Marocco Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market Download ASAQ Press pack, March 1st 2007 [PDF 890KB] Download ASAQ Newsletter, November 2009 [PDF 980KB] Read more about ASAQ project				ASAQ News
				Implementation progress More than 130 million treatments distributed ASAQ registered in 30 countries Technology transfer to African industry partner in preparation
				Recent Scientific Publications Malaria Journal, May 2011 Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience Malaria Journal, May 2011 The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership
				Recent Events No recent ASAQ events